Neothetics to price IPO of 4.3 million shares between $13.00, $15.00

Piper Jaffray and Guggenheim are joint bookrunners; Needham assists

By Devika Patel

Knoxville, Tenn., Nov. 10 – Neothetics, Inc. will sell 4.3 million common shares in its initial public offering with a 30-day greenshoe of 645,000 additional shares, according to a Form S-1/A filed Monday with the Securities and Exchange Commission. The deal was announced Oct. 17.

The shares will be sold at a price expected to fall between $13.00 and $15.00 per share.

Piper Jaffray and Guggenheim Securities are the bookrunning managers. Needham & Co. is the co-manager.

Proceeds will be used for clinical trials, development, working capital and other general corporate purposes.

The clinical-stage specialty pharmaceutical company is based in San Diego. It intends to list its common stock on the Nasdaq under the symbol “NEOT.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.